High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Dutcher, Janice P, Schwartzentruber, Douglas J, Kaufman, Howard L, Agarwala, Sanjiv S, Tarhini, Ahmad A, Lowder, James N, Atkins, Michael B
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6889624/
https://ncbi.nlm.nih.gov/pubmed/31546315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-014-0026-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados